NCT00223626View on ClinicalTrials.gov

Topiramate to Reduce Cocaine Dependence

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

December 31, 2010

Conditions
Cocaine-Related Disorders
Interventions
DRUG

Topiramate

the maximum topiramate test dose is 200 mg/d.

Trial Locations (2)

22911

University of Virginia CARE Center for Addiction Research & Education, Charlottesville

23294

UVA CARE Richmond, Richmond

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Bankole Johnson

OTHER

NCT00223626 - Topiramate to Reduce Cocaine Dependence | Biotech Hunter | Biotech Hunter